Results 231 to 240 of about 85,902 (266)
Some of the next articles are maybe not open access.
Delivery Strategies for Immune Checkpoint Blockade
Advanced Healthcare Materials, 2018AbstractImmune checkpoint blockade, which blocks the regulatory pathways that express on immune cells to improve antitumor immunological responses, is becoming one of the most promising approaches for antitumor therapy. This therapy has achieved important clinical advancement and provided a new opportunity against a variety of cancers.
Qian Chen +4 more
openaire +2 more sources
Combination of Photodynamic Therapy and Immune Checkpoint Blockade
2022Photodynamic therapy (PDT) for cancer not only strongly reduces tumor mass but can also induce or enhance immune responses against the tumor by causing the release of tumor antigen and danger signals from dying tumor cells. This supports combinations of PDT and immunotherapy for the treatment of advanced tumors for which single therapies are ...
Jan Willem, Kleinovink, Ferry, Ossendorp
openaire +2 more sources
Double immune checkpoint blockade in advanced NSCLC
Critical Reviews in Oncology/Hematology, 2020Immunotherapy-based options for patients with advanced non-small cell lung cancer (NSCLC) are increasing at an unprecedented pace, carrying the promise to prolong survival of this deadly disease. To maximize responses and extend benefit to a larger portion of patients, immunotherapy combination strategies are currently under investigation, with chemo ...
Annapaola Mariniello +3 more
openaire +2 more sources
Presurgical immune checkpoint blockade
Science, 2020Cancer Immunotherapy Checkpoint blockade immunotherapy using antibodies that inhibit the programmed cell death 1 (PD-1) or cytotoxic T lymphocyte–associated protein 4 (CTLA-4) pathways has resulted in unprecedented clinical outcomes for certain cancers such as melanoma. Topalian et al.
openaire +1 more source
Microbiome dynamics in immune checkpoint blockade
Trends in Endocrinology & MetabolismImmune checkpoint blockade (ICB) is one of the leading immunotherapies, although a variable extent of resistance has been observed among patients and across cancer types. Among the efforts underway to overcome this challenge, the microbiome has emerged as a factor affecting the responsiveness and efficacy of ICB.
Chae Won Kim +2 more
openaire +2 more sources
Immune checkpoint blockades therapy of melanoma
Science Bulletin, 2023Hong, Liu +3 more
openaire +2 more sources
Adjuvant immune checkpoint blockade revisited
The Lancet Oncology, 2023Sahar Barjesteh, van Waalwijk van Doorn-Khosrovani +6 more
openaire +2 more sources
Immune Checkpoint Blockade in Metastatic Urothelial Cancer
Journal of Clinical Oncology, 2017The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors’ suggested management approaches.
openaire +2 more sources